A Phase 1 interventional study of Placebo and THC in Drug Abuse, Intoxication by Drug and Impairment, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.
Sponsored by University of California, Los Angeles · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Substance-Related Disorders by University of California, Los Angeles — 5 open to participants now, 7 under way, none of them phase 3. Substance-Related Disorders · University of California, Los Angeles.
Among the 51 studies in Substance-Related Disorders by University of California, Los Angeles, this one is the 40th largest by planned enrollment of the 48 interventional ones that give a count, is the only one that started in 2026, is one of 10 in phase 1, and was the 44th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →5 of the 51 studies in Substance-Related Disorders by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–59 · Men only · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 21–55 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18–65 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 6 · Phase 3 4
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 125 across the 48 interventional studies, 423 across the 2 observational. Of the 41 that completed or were terminated, 9 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
2 of the studies in Substance-Related Disorders by University of California, Los Angeles that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067387University of California, Los AngelesEvaluation of Oral THC and CBD in Men and Women | 2027-06-15 |
| NCT06859710University of California, Los AngelesTHC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 51 studies in Substance-Related Disorders by University of California, Los Angeles, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
This double-blind placebo controlled, within-subject study study will assess testing devices that can measure biochemical markers in oral fluid and neurocognitive-performance markers of recent THC or CBD use. Other pharmacodynamic effects of oral THC or CBD will be determined and the pharmacokinetics of THC, CBD, and respective metabolites will be assessed in whole blood.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral placebo; sesame and MCT oil
Drug: Placebo
THC suspended in sesame oil
Drug: THC
CBD suspended in MCT oil
Drug: CBD
THC and CBD in sesame and MCT oil
Drug: THC + CBD
Oral placebo
Oral THC (20 mg)
Oral CBD (20 mg)
Drug pages: DronabinolStudies of DronabinolDronabinol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral THC (20 mg) + CBD (20 mg)
Ratings of subjective drug effects
Average and peak subjective ratings of drug effects associated with abuse liability as measured using visual analogue scales (VAS; 1-100mm).
Time frame: 6 hours
Concentration of THC, CBD and metabolites in whole blood
Peak blood levels of THC, CBD, 11-OH-THC, and THCCOOH as measured in ng/ml
Time frame: 6 hours
Behavioral task performance as assessed by the DRUID App Score
Composite score on the DRUID App, a measure of behavioral task performance (range 0-100) where lower scores indicate better performance
Time frame: 6 hours
Concentration of THC in oral fluid
Liquid chromatography-tandem mass spectrometry
Time frame: 6 hours
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jun 2027, 10 months after the start.
Of 30 non-industry phase 1 interventional studies under Substance-Related Disorders, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 46. This study's planned 10 months is below that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dronabinol · Cannabidiol
University of California, Los Angeles →